Study to Assess the Safety and Efficacy of SelK2 to Prevent Blood Clots in Patients Undergoing Total Knee Replacement

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 207 participants.

Also called NCT03812328

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose prevention
Phase
Phase 2
Enrolled
  • 207 participants (enrolled count) (from the registry)
Sponsor
Tetherex Pharmaceuticals Corporation (from the registry)
Registry
  • NCT NCT03812328
  • EudraCT 2018-003122-88
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Bulgaria, Latvia, Lithuania, Poland, Ukraine (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03812328. Randomized; single masking; primary purpose prevention. Start 2019-02-20 (actual); primary completion 2019-10-01 (actual). Results posted on 2020-11-24.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study to Assess the Safety and Efficacy of SelK2 to Prevent Blood Clots in Patients Undergoing Total Knee Replacement
Acronym
COURSE
Condition
Venous Thromboembolism
Intervention (Drug)
SelK2
Intervention (Biological)
Enoxaparin
Lead sponsor
Tetherex Pharmaceuticals Corporation (class: industry)

Record details

Record id
cardio:ct-nct03812328
Content hash
7c173624a16f7917515f21ef6c64cda432112ca7be48194de6969f0a9218ab9a